董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Avraham Ben Tzvi | 男 | Director | 55 | 未披露 | 未持股 | 2026-06-29 |
| Robert Liscouski | 男 | Chairman of the Board | 72 | 未披露 | 未持股 | 2026-06-29 |
| David Lazar | 男 | CEO and Director | 35 | 未披露 | 47700.00 | 2026-06-29 |
| David Natan | 男 | Director | 73 | 未披露 | 未持股 | 2026-06-29 |
| Peter O'Rourke | 男 | Director | 53 | 未披露 | 未持股 | 2026-06-29 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Caragol | 男 | Chief Financial Officer | 59 | 57.25万美元 | 36.79 | 2026-06-29 |
| David Lazar | 男 | CEO and Director | 35 | 未披露 | 47700.00 | 2026-06-29 |
董事简历
中英对照 | 中文 | 英文- Avraham Ben Tzvi
-
Avraham Ben Tzvi，2014年4月起，担任本公司的法律总顾问、企业秘书。2009-2014，他是Yigal Arnon & Co.的律师，除了其它企业和商业工作，他为公司和承销商提供服务，包括在美国上市的以色列公司发行、SEC相关文件的填制。2009年之前，他金融服务、制造、软件开发行业，担任各种职务，涉及业务开发、企业财务、银行事务。他在纽约的 Yeshiva University获得经济学士学位，在以色列Hod Hasharon的Sha'arei Mishpat College of Law 获得法律学士学位。
Avraham Ben Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical stage company advancing first in class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben Tzvi served as General Counsel and Company Secretary at Medig Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Prior to that he served as an attorney at one of Israel's leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on vario offerings by Israeli companies listing in the and on vario SEC related filings. Prior to becoming a lawyer, Mr. Ben Tzvi worked in several biness development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development indtries. Mr. Ben Tzvi has been serving as a member of the Board of Directors of Black Titan Corporation (NASDAQ: BTTC), a distributor of human capital management software solutions in Southeast Asia, since October 1, 2025, following the completion of a merger with Titan Pharmaceuticals Inc. where he served as a director beten August 2022 and the completion of the merger with Black Titan Corporation on October 1, 2025. Beten January 5, 2025 and April 2, 2025, Mr. Ben Tzvi served as a member of the Board of Directors of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) a pharmaceuticals development company. Beten October 15, 2024 and December 19, 2024, Mr. Ben Tzvi served as a member of the Board of Directors of LQR Hoe, Inc. (NASDAQ: YHC), a company in the wine and spirits e commerce sector. Beten March 25, 2024 and August 2, 2024, Mr. Ben Tzvi served as a member of the Board of Directors of OpGen, Inc. (NASDAQ: OPGN), a precision medicine company. Beten December 2023 and February 2025, Mr. Ben Tzvi served as a member of the Board of Directors of Minim, Inc. (NASDAQ: MINM), a company which delivered smart software driven communications products under the globally recognized Motorola brand and Minim trademark. Mr. Ben Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an L.L.B., magna cum laude from Sha'arei Mishpat College of Law in Hod HaSharon, Israel. Mr. Ben Tzvi is a licensed attorney and member of the Israel Bar Association and is also licensed as a Notary by the Israeli Ministry of Jtice. - Avraham Ben Tzvi，2014年4月起，担任本公司的法律总顾问、企业秘书。2009-2014，他是Yigal Arnon & Co.的律师，除了其它企业和商业工作，他为公司和承销商提供服务，包括在美国上市的以色列公司发行、SEC相关文件的填制。2009年之前，他金融服务、制造、软件开发行业，担任各种职务，涉及业务开发、企业财务、银行事务。他在纽约的 Yeshiva University获得经济学士学位，在以色列Hod Hasharon的Sha'arei Mishpat College of Law 获得法律学士学位。
- Avraham Ben Tzvi served as Chief Legal Officer and General Counsel of Purple Biotech Ltd. (formerly Kitov Pharma Ltd.) (NASDAQ/TASE: PPBT), a clinical stage company advancing first in class therapies to overcome tumor immune evasion and drug resistance, from November 2015 until April 2020. Prior to that, Mr. Ben Tzvi served as General Counsel and Company Secretary at Medig Ltd. (NASDAQ/TASE: MDGS), a minimally invasive endosurgical tools medical device and miniaturized imaging equipment company, from April 2014 until November 2015. Prior to that he served as an attorney at one of Israel's leading international law firms where, amongst other corporate and commercial work, he advised companies and underwriters on vario offerings by Israeli companies listing in the and on vario SEC related filings. Prior to becoming a lawyer, Mr. Ben Tzvi worked in several biness development, corporate finance and banking roles at companies in the financial services, lithium battery manufacturing and software development indtries. Mr. Ben Tzvi has been serving as a member of the Board of Directors of Black Titan Corporation (NASDAQ: BTTC), a distributor of human capital management software solutions in Southeast Asia, since October 1, 2025, following the completion of a merger with Titan Pharmaceuticals Inc. where he served as a director beten August 2022 and the completion of the merger with Black Titan Corporation on October 1, 2025. Beten January 5, 2025 and April 2, 2025, Mr. Ben Tzvi served as a member of the Board of Directors of Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) a pharmaceuticals development company. Beten October 15, 2024 and December 19, 2024, Mr. Ben Tzvi served as a member of the Board of Directors of LQR Hoe, Inc. (NASDAQ: YHC), a company in the wine and spirits e commerce sector. Beten March 25, 2024 and August 2, 2024, Mr. Ben Tzvi served as a member of the Board of Directors of OpGen, Inc. (NASDAQ: OPGN), a precision medicine company. Beten December 2023 and February 2025, Mr. Ben Tzvi served as a member of the Board of Directors of Minim, Inc. (NASDAQ: MINM), a company which delivered smart software driven communications products under the globally recognized Motorola brand and Minim trademark. Mr. Ben Tzvi holds a B.A., magna cum laude, in Economics from Yeshiva University in New York and an L.L.B., magna cum laude from Sha'arei Mishpat College of Law in Hod HaSharon, Israel. Mr. Ben Tzvi is a licensed attorney and member of the Israel Bar Association and is also licensed as a Notary by the Israeli Ministry of Jtice.
- Robert Liscouski
-
Robert Liscouski是量子计算公司的董事长兼首席执行官。Liscouski是公认的安全行业领导者，致力于评估，减轻和管理私营企业以及州和联邦政府机构的物理和网络安全风险。Liscouski先生在领导创新初创公司和扭转公司以及为大型政府组织构建程序方面拥有丰富的经验，并被公认为识别新兴安全技术的领导者。他担任政府和私营部门高级官员的“可信顾问”，在物理和网络安全、危机管理、组织发展和战略规划等领域提供指导。Liscouski先生的职业生涯跨越了地方执法、政府和私营部门的高级职位，从运营到高级领导和董事会。他的职业生涯始于一名卧底和凶杀案调查员，他曾担任外交安全局的特别特工，并晋升为联邦政府的高级职位，在那里他曾担任情报界的高级顾问，并被George W.Bush总统任命为国土安全部负责基础设施保护的第一助理部长。他最近担任一家上市公司的总裁，该公司成为爆炸物痕迹检测行业的领导者，最终将该技术出售给了L3Communications。利斯库斯基经常为CNBC、CNN、福克斯新闻以及其他商业和安全媒体撰写有关国土安全和恐怖主义问题的文章。
Robert Liscouski served as the Chairman of the Board of Quantum Computing, Inc. from February 2018 to December 2024. From March 2018 through January 2024, Mr. Liscouski served as Chief Executive Officer and President of Quantum Computing, Inc. Prior to that, Mr. Liscouski served as Chairman and Founder of Convergent Risk Group LLC, an enterprise security risk management firm specializing in the convergence of physical and cyber risk, from January 2011 through May 2019 and as President of Implant Sciences Corp., a public company that became a leader in the explosive trace detection industry culminating in the sale of the technology to L3 Communications in January 2017. Mr. Liscouski is a proven security professional, thought leader and successful entrepreneur with over 35 years of senior level security operational and company leadership experience in government and public and private companies. Mr. Liscouski has extensive experience in assessing, mitigating and managing physical and cybersecurity risk in private sector enterprises and state and federal government agencies. Mr. Liscouski has experience in leading innovative start up and turnaround companies as well as building programs for large government organizations and in identifying emerging security technologies. He serves as a "Trusted Advisor" to senior officials within government and private sector, providing guidance in areas such as physical and cyber security, crisis management, organizational development and strategic planning. Mr. Liscouski's career has spanned local law enforcement, senior government and private sector positions from operations to senior leadership and boards of directors. He served as a senior advisor to the intelligence community and was appointed by President George W. Bush as the first Assistant Secretary for Infrastructure Protection at the Department of Homeland Security. Mr. Liscouski is a Founder and Chairman of the Board of the National Child Protection Task Force, a 501(c)(3) charitable organization, and served on the Board of Clean Coal Technologies Inc. from 2019 until December 2020. He received his Bachelor of Science degree in Criminal Justice from John Jay College and his MPA in Public Administration from the Kennedy School of Government, Harvard University. - Robert Liscouski是量子计算公司的董事长兼首席执行官。Liscouski是公认的安全行业领导者，致力于评估，减轻和管理私营企业以及州和联邦政府机构的物理和网络安全风险。Liscouski先生在领导创新初创公司和扭转公司以及为大型政府组织构建程序方面拥有丰富的经验，并被公认为识别新兴安全技术的领导者。他担任政府和私营部门高级官员的“可信顾问”，在物理和网络安全、危机管理、组织发展和战略规划等领域提供指导。Liscouski先生的职业生涯跨越了地方执法、政府和私营部门的高级职位，从运营到高级领导和董事会。他的职业生涯始于一名卧底和凶杀案调查员，他曾担任外交安全局的特别特工，并晋升为联邦政府的高级职位，在那里他曾担任情报界的高级顾问，并被George W.Bush总统任命为国土安全部负责基础设施保护的第一助理部长。他最近担任一家上市公司的总裁，该公司成为爆炸物痕迹检测行业的领导者，最终将该技术出售给了L3Communications。利斯库斯基经常为CNBC、CNN、福克斯新闻以及其他商业和安全媒体撰写有关国土安全和恐怖主义问题的文章。
- Robert Liscouski served as the Chairman of the Board of Quantum Computing, Inc. from February 2018 to December 2024. From March 2018 through January 2024, Mr. Liscouski served as Chief Executive Officer and President of Quantum Computing, Inc. Prior to that, Mr. Liscouski served as Chairman and Founder of Convergent Risk Group LLC, an enterprise security risk management firm specializing in the convergence of physical and cyber risk, from January 2011 through May 2019 and as President of Implant Sciences Corp., a public company that became a leader in the explosive trace detection industry culminating in the sale of the technology to L3 Communications in January 2017. Mr. Liscouski is a proven security professional, thought leader and successful entrepreneur with over 35 years of senior level security operational and company leadership experience in government and public and private companies. Mr. Liscouski has extensive experience in assessing, mitigating and managing physical and cybersecurity risk in private sector enterprises and state and federal government agencies. Mr. Liscouski has experience in leading innovative start up and turnaround companies as well as building programs for large government organizations and in identifying emerging security technologies. He serves as a "Trusted Advisor" to senior officials within government and private sector, providing guidance in areas such as physical and cyber security, crisis management, organizational development and strategic planning. Mr. Liscouski's career has spanned local law enforcement, senior government and private sector positions from operations to senior leadership and boards of directors. He served as a senior advisor to the intelligence community and was appointed by President George W. Bush as the first Assistant Secretary for Infrastructure Protection at the Department of Homeland Security. Mr. Liscouski is a Founder and Chairman of the Board of the National Child Protection Task Force, a 501(c)(3) charitable organization, and served on the Board of Clean Coal Technologies Inc. from 2019 until December 2020. He received his Bachelor of Science degree in Criminal Justice from John Jay College and his MPA in Public Administration from the Kennedy School of Government, Harvard University.
- David Lazar
-
David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
David Lazar currently serves as the CEO of the Company. Previously David served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026, and of Sow Good from January 2026 to May 2026. David previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August November 2025. Prior to that, David previously served as director on the board of directors of FiEE, Inc. (NASDAQ: FIEE) (formerly Minim, Inc.) where he also previously served as the CEO and CFO from December 2023 to February 2025. David served as interim CEO and principal Financial Officer of Bio Green Med Solution Inc. (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.), from January 2, 2025, through February 26, 2025. David served as the CEO of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.) from August 2022 to April 2024, where he also served as a Director and board Chairman from August 2022 until October 2023. David also served as the CEO and Chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to August 2024. David also served as the president and a member of the board of directors of LQR House Inc. (NASDAQ: YHC) from October 2024 to April 2025. David served as the CEO of Activist Investing from March 2018 to April 2022. - David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
- David Lazar currently serves as the CEO of the Company. Previously David served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026, and of Sow Good from January 2026 to May 2026. David previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August November 2025. Prior to that, David previously served as director on the board of directors of FiEE, Inc. (NASDAQ: FIEE) (formerly Minim, Inc.) where he also previously served as the CEO and CFO from December 2023 to February 2025. David served as interim CEO and principal Financial Officer of Bio Green Med Solution Inc. (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.), from January 2, 2025, through February 26, 2025. David served as the CEO of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.) from August 2022 to April 2024, where he also served as a Director and board Chairman from August 2022 until October 2023. David also served as the CEO and Chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to August 2024. David also served as the president and a member of the board of directors of LQR House Inc. (NASDAQ: YHC) from October 2024 to April 2025. David served as the CEO of Activist Investing from March 2018 to April 2022.
- David Natan
-
David Natan自2026年1月起在Indaptus Therapeutics, Inc.董事会任职，目前担任Natan & Associates，LLC的总裁兼首席执行官，该公司是一家咨询公司，自2007年起为国内和国际各行业的上市公司和私营公司提供首席财务官服务。从2010年到2020年5月，Natan先生担任ForceField Energy，Inc.（OTCMKTS：FNRG）的首席执行官，该公司专注于太阳能行业和源自中国的LED照明产品。自2002年2月至2007年11月，Natan先生担任Pharma Net Development Group，Inc.（一家药物开发服务和临床试验公司）的报告执行副总裁兼首席财务官，并于1995年6月至2002年2月担任Global TechNovations，Inc.（一家机油分析仪器以及扬声器和扬声器组件的制造商和营销商）的首席财务官和副总裁。在此之前，Natan先生曾在全球会计和咨询公司德勤会计师事务所（Deloitte & Touche LLP）担任过各种职责不断增加的职务。Natan先生目前自2022年2月起担任制药和营养补充剂公司Sunshine Biopharma, Inc.（纳斯达克：SBFM）的董事会成员和审计委员会主席。此外，自2024年4月以来，Natan先生主要在香港担任FIEE公司的董事会成员和审计委员会主席，该公司是一家专门从事SaaS解决方案和人工智能软件开发的技术公司。在此之前，Natan先生曾担任以下上市公司的董事：Global TechNovations、Forcefield Energy、Black Titan（纳斯达克：BTTC）、Vivakor Inc.（纳斯达克：VIVK）、Net Brands Corp.（OTC：NBND）、OpGen Inc.（OTC：OPGN）以及Bio Green Med Solutions（TERM0纳斯达克：BGMS）。Natan先生是一名注册会计师（非在职），拥有波士顿大学经济学学士学位，并被任命为经济学领域的国际荣誉学会Omicron Delta Epsilon。
David Natan has served on Indaptus Therapeutics, Inc.'s Board since January 2026 and currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007. From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products sourced from China. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served in various roles of increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally, since April 2024, Mr. Natan has served as a member of the Board of Directors and Audit Committee Chair of FIEE, Inc., a technology company specializing in SaaS solutions and AI software development, primarily in Hong Kong. Previously, Mr. Natan has served as a director for the following public companies: Global Technovations, Forcefield Energy, Black Titan (Nasdaq: BTTC), Vivakor Inc. (Nasdaq: VIVK), Net Brands Corp. (OTC: NBND), OpGen Inc. (OTC: OPGN), and Bio Green Med Solutions (Nasdaq: BGMS). Mr. Natan is a CPA (inactive), holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon, an international honor society in the field of Economics. - David Natan自2026年1月起在Indaptus Therapeutics, Inc.董事会任职，目前担任Natan & Associates，LLC的总裁兼首席执行官，该公司是一家咨询公司，自2007年起为国内和国际各行业的上市公司和私营公司提供首席财务官服务。从2010年到2020年5月，Natan先生担任ForceField Energy，Inc.（OTCMKTS：FNRG）的首席执行官，该公司专注于太阳能行业和源自中国的LED照明产品。自2002年2月至2007年11月，Natan先生担任Pharma Net Development Group，Inc.（一家药物开发服务和临床试验公司）的报告执行副总裁兼首席财务官，并于1995年6月至2002年2月担任Global TechNovations，Inc.（一家机油分析仪器以及扬声器和扬声器组件的制造商和营销商）的首席财务官和副总裁。在此之前，Natan先生曾在全球会计和咨询公司德勤会计师事务所（Deloitte & Touche LLP）担任过各种职责不断增加的职务。Natan先生目前自2022年2月起担任制药和营养补充剂公司Sunshine Biopharma, Inc.（纳斯达克：SBFM）的董事会成员和审计委员会主席。此外，自2024年4月以来，Natan先生主要在香港担任FIEE公司的董事会成员和审计委员会主席，该公司是一家专门从事SaaS解决方案和人工智能软件开发的技术公司。在此之前，Natan先生曾担任以下上市公司的董事：Global TechNovations、Forcefield Energy、Black Titan（纳斯达克：BTTC）、Vivakor Inc.（纳斯达克：VIVK）、Net Brands Corp.（OTC：NBND）、OpGen Inc.（OTC：OPGN）以及Bio Green Med Solutions（TERM0纳斯达克：BGMS）。Natan先生是一名注册会计师（非在职），拥有波士顿大学经济学学士学位，并被任命为经济学领域的国际荣誉学会Omicron Delta Epsilon。
- David Natan has served on Indaptus Therapeutics, Inc.'s Board since January 2026 and currently serves as President and Chief Executive Officer of Natan & Associates, LLC, a consulting firm offering chief financial officer services to public and private companies in a variety of industries, both domestically and internationally, since 2007. From 2010 to May 2020, Mr. Natan served as Chief Executive Officer of ForceField Energy, Inc. (OTCMKTS: FNRG), a company focused on the solar industry and LED lighting products sourced from China. From February 2002 to November 2007, Mr. Natan served as Executive Vice President of Reporting and Chief Financial Officer of Pharma Net Development Group, Inc., a drug development services and clinical trials company, and, from June 1995 to February 2002, as Chief Financial Officer and Vice President of Global Technovations, Inc., a manufacturer and marketer of oil analysis instruments and speakers and speaker components. Prior to that, Mr. Natan served in various roles of increasing responsibility with Deloitte & Touche LLP, a global accounting and consulting firm. Mr. Natan currently serves as a member of the Board of Directors and Chair of the Audit Committee of Sunshine Biopharma, Inc. (Nasdaq: SBFM), a pharmaceutical and nutritional supplement company, since February 2022. Additionally, since April 2024, Mr. Natan has served as a member of the Board of Directors and Audit Committee Chair of FIEE, Inc., a technology company specializing in SaaS solutions and AI software development, primarily in Hong Kong. Previously, Mr. Natan has served as a director for the following public companies: Global Technovations, Forcefield Energy, Black Titan (Nasdaq: BTTC), Vivakor Inc. (Nasdaq: VIVK), Net Brands Corp. (OTC: NBND), OpGen Inc. (OTC: OPGN), and Bio Green Med Solutions (Nasdaq: BGMS). Mr. Natan is a CPA (inactive), holds a B.A. in Economics from Boston University, and was appointed to Omicron Delta Epsilon, an international honor society in the field of Economics.
- Peter O'Rourke
-
Peter O'Rourke自2026年5月起担任董事会董事。O'Rourke先生于2018年12月至今在TCI Partners担任管理合伙人，该公司是一家专注于医疗保健、航空航天和公共部门的咨询公司。从2020年11月至2022年7月，奥罗克先生担任Western Magnesium Corporation的总裁兼董事，在该公司的技术试点阶段，他创建了美国运营战略和团队，并领导企业和国防业务发展、政府事务和通信。2017年1月至2018年12月，奥罗克先生担任退伍军人事务部代理秘书兼参谋长。2015年5月至2016年7月，O'Rourke先生担任咨询公司Calibre Systems，Inc.的负责人。奥罗克还曾在美国海军和空军任职。从2021年6月至2025年7月，O'Rourke先生担任NorthView Acquisition Corporation的董事会主席。自2025年7月起，O'Rourke先生担任ProFusa，Inc.的首席独立董事兼提名和治理委员会主席，并于2020年7月至今担任AXIM Biotechnologies的董事。奥罗克先生在诺克斯维尔的田纳西大学获得政治学学士学位，并在美国空军理工学院获得物流和供应链管理理学硕士学位。
Peter O'Rourke has served as a director of the Board since May 2026. Mr. O'Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector, from December 2018 to present. From November 2020 July 2022, Mr. O'Rourke was President and Director for Western Magnesium Corporation where he created the U.S. operations strategy and team during the technology pilot phase of the company, and led enterprise and defense business development, government affairs, and communications. From January 2017 to December 2018, Mr. O'Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O'Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O'Rourke also served in both the U.S. Navy and Air Force. From June 2021 to July 2025 Mr. O'Rourke served as the Chairman of the Board of Directors for NorthView Acquisition Corporation. Since July 2025, Mr. O'Rourke has been the Lead Independent Director and Chairman of the Nominations and Governance Committee of ProFusa, Inc., and he has served as Director for AXIM Biotechnologies from July 2020 to present. Mr. O'Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force's Institute of Technology. - Peter O'Rourke自2026年5月起担任董事会董事。O'Rourke先生于2018年12月至今在TCI Partners担任管理合伙人，该公司是一家专注于医疗保健、航空航天和公共部门的咨询公司。从2020年11月至2022年7月，奥罗克先生担任Western Magnesium Corporation的总裁兼董事，在该公司的技术试点阶段，他创建了美国运营战略和团队，并领导企业和国防业务发展、政府事务和通信。2017年1月至2018年12月，奥罗克先生担任退伍军人事务部代理秘书兼参谋长。2015年5月至2016年7月，O'Rourke先生担任咨询公司Calibre Systems，Inc.的负责人。奥罗克还曾在美国海军和空军任职。从2021年6月至2025年7月，O'Rourke先生担任NorthView Acquisition Corporation的董事会主席。自2025年7月起，O'Rourke先生担任ProFusa，Inc.的首席独立董事兼提名和治理委员会主席，并于2020年7月至今担任AXIM Biotechnologies的董事。奥罗克先生在诺克斯维尔的田纳西大学获得政治学学士学位，并在美国空军理工学院获得物流和供应链管理理学硕士学位。
- Peter O'Rourke has served as a director of the Board since May 2026. Mr. O'Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector, from December 2018 to present. From November 2020 July 2022, Mr. O'Rourke was President and Director for Western Magnesium Corporation where he created the U.S. operations strategy and team during the technology pilot phase of the company, and led enterprise and defense business development, government affairs, and communications. From January 2017 to December 2018, Mr. O'Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O'Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O'Rourke also served in both the U.S. Navy and Air Force. From June 2021 to July 2025 Mr. O'Rourke served as the Chairman of the Board of Directors for NorthView Acquisition Corporation. Since July 2025, Mr. O'Rourke has been the Lead Independent Director and Chairman of the Nominations and Governance Committee of ProFusa, Inc., and he has served as Director for AXIM Biotechnologies from July 2020 to present. Mr. O'Rourke received a Bachelor of Arts in Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air Force's Institute of Technology.
高管简历
中英对照 | 中文 | 英文- William Caragol
William Caragol于2021年6月30日被任命为董事，自2021年7月起担任Mainz Biomed N.V.的首席财务官，纳斯达克代码:MYNZ，这是一家领先的易于使用的诊断解决方案提供商。从2018年至今，Caragol先生还一直担任公司咨询公司Quidem LLC的董事总经理。自2015年以来，Caragol先生一直担任ThermoMedics，Inc.（一家医疗诊断设备公司）的董事会主席。自2021年2月起，Caragol先生还担任GreenBox POS（纳斯达克代码:GBOX）的董事会成员和审计委员会主席，2012年至2018年，Caragol先生担任PositiveID的董事长兼首席执行官，一家公开上市的控股公司，拥有生物检测系统，分子诊断和糖尿病管理产品领域的产品组合。Caragol先生在Washington&Lee University获得工商管理和会计学士学位，是美国注册会计师协会的成员。
William Caragol is Quantum Cyber N.V.'s Chief Financial Officer and has over thirty years of experience working with growth stage technology companies. In 2018, he founded and is the Managing Director of Quidem LLC, a corporate strategic and financial advisory firm. From November 2021 to September 2025, Mr. Caragol served as the Chief Operating Officer and Chief Financial Officer of Iron Horse Acquisitions Corp. (NASDAQ: IROH). Since November 2024 Mr. Caragol has served as a director and CFO of Iron Horse Acquisition II Corp. (NASDAQ: IRHO). Since July 2023, Mr. Caragol has also been on the board of directors and has been Chairman of the audit committee of DeFi Development Corp. (NASDAQ: DFDV), serves on the board of Worksport Ltd. (NASDAQ: WKSP) since June 2021, and he served on the board of directors of Greenbox POS (NASDAQ: GBOX) from 2021 to April 2023. Mr. Caragol earned a B.S. in business administration and accounting from Washington & Lee University and is a member of the American Institute of Certified Public Accountants.- William Caragol于2021年6月30日被任命为董事，自2021年7月起担任Mainz Biomed N.V.的首席财务官，纳斯达克代码:MYNZ，这是一家领先的易于使用的诊断解决方案提供商。从2018年至今，Caragol先生还一直担任公司咨询公司Quidem LLC的董事总经理。自2015年以来，Caragol先生一直担任ThermoMedics，Inc.（一家医疗诊断设备公司）的董事会主席。自2021年2月起，Caragol先生还担任GreenBox POS（纳斯达克代码:GBOX）的董事会成员和审计委员会主席，2012年至2018年，Caragol先生担任PositiveID的董事长兼首席执行官，一家公开上市的控股公司，拥有生物检测系统，分子诊断和糖尿病管理产品领域的产品组合。Caragol先生在Washington&Lee University获得工商管理和会计学士学位，是美国注册会计师协会的成员。
- William Caragol is Quantum Cyber N.V.'s Chief Financial Officer and has over thirty years of experience working with growth stage technology companies. In 2018, he founded and is the Managing Director of Quidem LLC, a corporate strategic and financial advisory firm. From November 2021 to September 2025, Mr. Caragol served as the Chief Operating Officer and Chief Financial Officer of Iron Horse Acquisitions Corp. (NASDAQ: IROH). Since November 2024 Mr. Caragol has served as a director and CFO of Iron Horse Acquisition II Corp. (NASDAQ: IRHO). Since July 2023, Mr. Caragol has also been on the board of directors and has been Chairman of the audit committee of DeFi Development Corp. (NASDAQ: DFDV), serves on the board of Worksport Ltd. (NASDAQ: WKSP) since June 2021, and he served on the board of directors of Greenbox POS (NASDAQ: GBOX) from 2021 to April 2023. Mr. Caragol earned a B.S. in business administration and accounting from Washington & Lee University and is a member of the American Institute of Certified Public Accountants.
- David Lazar
David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
David Lazar currently serves as the CEO of the Company. Previously David served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026, and of Sow Good from January 2026 to May 2026. David previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August November 2025. Prior to that, David previously served as director on the board of directors of FiEE, Inc. (NASDAQ: FIEE) (formerly Minim, Inc.) where he also previously served as the CEO and CFO from December 2023 to February 2025. David served as interim CEO and principal Financial Officer of Bio Green Med Solution Inc. (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.), from January 2, 2025, through February 26, 2025. David served as the CEO of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.) from August 2022 to April 2024, where he also served as a Director and board Chairman from August 2022 until October 2023. David also served as the CEO and Chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to August 2024. David also served as the president and a member of the board of directors of LQR House Inc. (NASDAQ: YHC) from October 2024 to April 2025. David served as the CEO of Activist Investing from March 2018 to April 2022.- David Lazar自2025年11月起担任KALA BIO，Inc.董事会成员兼首席执行官。他于2025年8月至2025年10月担任Novabay Pharmaceuticals, Inc.（NASDAQ：NBY）的首席执行官，该公司是一家上市生物制药公司previoly，专注于开发和销售眼部护理、伤口护理和皮肤护理产品。在此之前，Lazar Previoly先生在FiEE，Inc.（前身为Minim, Inc.）（纳斯达克股票代码：FIEE）的董事会担任董事，他还在2023年12月至2025年2月期间担任首席执行官和首席财务官。Lazar先生于2025年1月2日至2025年2月26日期间担任Bio Green Med Solution Inc.（纳斯达克股票代码：BGMS）的临时首席执行官和首席财务官。Lazar先生于2022年8月至2024年4月期间担任在纳斯达克上市的Black Titan Corporation（NASDAQ：BTTC）的首席执行官，并于2022年8月至2023年10月期间担任董事和董事会主席。Lazar先生还于2024年3月至2024年8月期间担任OpGen公司（OTC：OPGN）的首席执行官兼董事会主席。Lazar先生还曾在2024年10月至2025年4月期间担任LQR Hoe Inc.（纳斯达克股票代码：YHC）的总裁和董事会成员。Lazar先生于2018年3月至2022年4月担任Activist Investing的首席执行官。
- David Lazar currently serves as the CEO of the Company. Previously David served as the CEO and Chairman of Kala Bio Inc. (NASDAQ: KALA) from December 2025 to February 2026, and of Sow Good from January 2026 to May 2026. David previously served as CEO & Chairman of Novabay Pharmaceuticals, Inc. (NASDAQ: NBY) from August November 2025. Prior to that, David previously served as director on the board of directors of FiEE, Inc. (NASDAQ: FIEE) (formerly Minim, Inc.) where he also previously served as the CEO and CFO from December 2023 to February 2025. David served as interim CEO and principal Financial Officer of Bio Green Med Solution Inc. (NASDAQ: BGMS) (formerly Cyclacel Pharmaceuticals, Inc.), from January 2, 2025, through February 26, 2025. David served as the CEO of Black Titan Corporation listed on Nasdaq (NASDAQ: BTTC) (formerly Titan Pharmaceuticals, Inc.) from August 2022 to April 2024, where he also served as a Director and board Chairman from August 2022 until October 2023. David also served as the CEO and Chairman of the board of directors of OpGen, Inc. (OTC: OPGN) from March 2024 to August 2024. David also served as the president and a member of the board of directors of LQR House Inc. (NASDAQ: YHC) from October 2024 to April 2025. David served as the CEO of Activist Investing from March 2018 to April 2022.